Low-dose brimonidine tartrate 0.025%
DRUG DEVELOPMENT · GERALD HORN, MD
One idea.
Two medicines.
A career-long inquiry into what happens when a molecule is made more selective, a dose is made smaller, and physiology is asked to do less—but do it precisely.
Aceclidine ophthalmic solution 1.44%
01
THE THROUGHLINE
Precision before power.
The same design instinct shaped both programs: identify the smallest physiologic target that can create the desired effect, then reduce activity everywhere else.
Luminesse began with an unusually low concentration of a highly selective α2-adrenergic agonist. PRX-100 began with a pupil-selective miotic intended to expand depth of focus while sparing the ciliary muscle. The programs became LUMIFY and VIZZ.
PROGRAM 02 · PRESBYOPIA
PRX-100 → LNZ100 → VIZZThe camera
inside the eye.
VIZZ uses aceclidine to create a small pupil—an optical aperture that extends depth of focus from distance toward intermediate and near vision.
APERTURE
Wide pupilSmall pupil
ILLUSTRATIVE DEPTH OF FIELD
∞DISTANCE
60 cmCOMPUTER
40 cmREADING
The distances are familiar examples, not VIZZ efficacy endpoints. The FDA endpoint was a ≥3-line gain in near acuity without losing more than one line of distance acuity.
Pilocarpine / carbachol
Broader muscarinic stimulation can constrict the pupil and stimulate the ciliary muscle, increasing accommodation and the possibility of accommodative symptoms.
Pupil-selective
FDA reviewers described VIZZ as pupillary-selective and ciliary-muscle-sparing: iris sphincter contraction creates a roughly 1.5–2.0 mm pinhole pupil with only modest pressure-lowering effect.
2015PRX-100 Phase 2 study began
2023CLARITY 1 & 2 Phase 3 studies
31 JUL 2025FDA approval of VIZZ
OCT 2025U.S. commercial launch
PROGRAM 01 · OCULAR REDNESS
LUMINESSE → LUMIFYFrom 0.2%
to 0.025%.
The discovery was not a new molecule. It was a new concentration—and a different vascular effect.
0.2%
Conventional glaucoma-strength brimonidine
0.025%
LUMIFY redness-reliever concentration
At low concentration, the clinical program pursued rapid redness reduction with less tachyphylaxis and rebound than were associated with older OTC vasoconstrictors.
The FDA review found a potential advantage in the absence of tachyphylaxis or rebound congestion. In diary data, reported rebound was 11.1% with brimonidine and 15.8% with vehicle—not literally zero, and therefore presented here with the regulatory wording rather than an absolute claim.
INVENTION, PATENT & LICENSING RECORD
From invention to market.
Gerald Horn’s patent foundation
Gerald Horn is the named inventor on the low-dose brimonidine patent family underlying the ocular-redness work, which claims priority to August 1, 2008. He is also the named inventor on the eye-whitening family, which claims priority to December 17, 2009. U.S. Patent No. 8,293,742—covering reduction of eye redness with low-concentration brimonidine—issued to Horn as inventor on October 23, 2012.
Exclusive global license
Bausch + Lomb announced that it had acquired an exclusive global license to Eye Therapies’ ocular-redness platform. The announcement identified Eye Therapies, LLC as Bausch + Lomb’s development collaborator.
FDA application under the proposed name Luminesse
Bausch & Lomb submitted NDA 208144 for brimonidine tartrate ophthalmic solution 0.025%. FDA records show that the proposed name Luminesse was not accepted because of possible confusion with Luminess cosmetic products.
FDA approval as LUMIFY
The FDA approved LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) for relief of eye redness due to minor eye irritations. Bausch + Lomb launched the product in the United States on May 7, 2018.
Attribution. Gerald Horn is the named inventor on the cited foundational patents. The invention and patent record precede the 2013 licensing transaction. Public records identify Eye Therapies as the licensor of the 0.025% formulation and LUMIFY-related patents; Bausch & Lomb was the NDA applicant and commercialized the product. LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates. This chronology does not assign a corporate formation date to Eye Therapies or imply current affiliation with or endorsement by Bausch + Lomb.
A PERSONAL SCIENTIFIC THESIS
The post-capillary venule.
“My most profound discovery is the possibility that very-low-dose, highly selective α2 agonists can reduce pathologic vascular leakage by constricting the post-capillary venule.”
The patent record proposes low concentrations of selective α2-adrenergic agonists—including brimonidine and dexmedetomidine—to reduce vascular permeability and VEGF-induced post-capillary venular leakage. It extends the hypothesis to pulmonary disease and acute lung injury.
Research status. This is an inventor’s mechanistic hypothesis and patent position—not an FDA-approved therapy for septic, toxic, anaphylactic, endotoxin, tampon-associated, or other forms of systemic shock. Any future clinical claim would require controlled human evidence and regulatory review.
PROPOSED MICROVASCULAR MODEL
ARTERIOLE
POST-CAPILLARY VENULE
Proposed target: selective constriction of smaller vessels with reduced leakage, while minimizing larger-vessel α1 activity.
Read the vascular-permeability patent application ↗02
INTELLECTUAL PROPERTY
Patent families,
organized by company.
Strategic family view of the U.S. record. Each number opens the public patent record; each company card links to the full, continuously updated assignee index.
OCULAR REDNESS · VASCULAR SELECTIVITYEye Therapies, LLC14 cited U.S. grants +
Foundational low-dose α2 work spanning eye whitening, vision, nasal disease, vasoconstriction, and vascular permeability.
US 8,293,742Preferential vasoconstrictionUS 8,765,758Eye whiteningUS 8,952,011Nasal conditionsUS 8,987,270Selective α2 formulationsUS 9,259,425Eye whiteningUS 11,026,884Improving visionUS 11,596,600Vasoconstriction compositionsUS 11,717,478Improving visionUS 11,833,245Vasoconstriction compositionsUS 11,992,488Vasoconstriction compositionsUS 12,151,022Improving visionUS 12,246,013Vasoconstriction compositionsUS 12,311,050Vasoconstriction compositionsUS 12,514,857Vasoconstriction compositionsUS 2010/0197694Vascular permeability · published application
View the live Eye Therapies assignee record ↗PRESBYOPIA · EARLY CLINICAL PLATFORMPresbyopia Therapies, LLC5 cited U.S. records +
PRX-100 and the early aceclidine platform: composition, stabilization, contact-lens delivery, and combination approaches.
US 2015/0065511Aceclidine combinationsUS 10,052,313Aceclidine + polyolUS 10,064,818Pilocarpine + tropicamideUS 10,307,408Contact-lens compositionsUS 10,617,763Aceclidine + cryoprotectant
View the live Presbyopia Therapies record ↗PRESBYOPIA · LATE-STAGE / COMMERCIALLENZ Therapeutics10 cited U.S. records +
Aceclidine compositions, derivatives, storage stability, administration protocols, and adjacent vision applications. Gerald Horn is identified in LENZ materials as founder and advisor.
US 11,179,327Aceclidine compositionUS 11,179,328Aceclidine compositionUS 11,214,569Quinuclidine prodrugsUS 11,273,150Aceclidine storageUS 11,344,538Treating myopiaUS 11,648,247Aceclidine + brimonidineUS 12,128,036Storage-stable ophthalmic drugsUS 12,180,206Aceclidine derivativesUS 12,414,942Administration protocolsUS 12,653,779Ophthalmic compositions
GLAUCOMA · NASAL · DRUG DELIVERYGNT / Glaucoma & Nasal TherapiesKey U.S. records +
Earlier platform work spanning glaucoma, inhibition of VEGF signaling, and ophthalmic delivery vehicles.
US 8,445,526Glaucoma treatmentUS 8,912,225Inhibiting VEGF productionUS 8,999,938Ophthalmic lipophilic vehicle
View Gerald Horn’s complete live inventor index ↗Scope note. Patent families evolve through continuations, assignments, national-stage filings, grants, expirations, and abandonments. This page emphasizes the U.S. family record most relevant to the programs above and links to live public indexes for the complete current record. It is not a legal opinion.
THE WORK, IN ONE SENTENCE